FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Neuropathic Pain Market Overview:

According to FutureWise analysis the market for neuropathic pain in 2023 is US$ 7.56 billion, and is expected to reach US$ 12.44 billion by 2031 at a CAGR of 6.40%.

Neuropathic pain is a kind of persistent pain caused by nervous system injury or malfunction. In contrast to acute pain, which is a natural response to injury or sickness, neuropathic pain is a chronic condition that remains long after the underlying cause of the pain has been addressed. It is a disabling disorder that can have a substantial influence on a person's quality of life. A multitude of reasons, including injury, infection, and illness, can result in neuropathic pain. It is frequently connected with diabetes, multiple sclerosis, and spinal cord injury. The pain may be described as burning, tingling, or shooting, and it may be constant or intermittent. In some cases, even a light touch or mild pressure can trigger intense pain.

Because neuropathic pain is a complex condition, it can be difficult to treat with traditional pain medications. While opioids and other painkillers may provide temporary relief, they are often ineffective in managing the underlying condition that is causing the pain. In addition, the prolonged use of these drugs may result in addiction and other undesirable side effects. New neuropathic pain therapies have thus attracted a lot of attention. These treatments may include drugs that target specific nerve pathways involved in pain signaling, as well as non-pharmacological interventions such as physical therapy and acupuncture. Researchers are also exploring the use of medical cannabis and other alternative therapies to manage neuropathic pain.

FutureWise Market Research has published a report that provides an insightful analysis of Neuropathic Pain Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Neuropathic Pain Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

Major players included in the Neuropathic Pain Market:

Pfizer, Inc.
Johnson & Johnson Services, Inc.
Sanofi S.A.
Eily Lily and Company
GlaxoSmithKline PLC
Biogen Idec.
Bristol-Myers Squibb
Baxter Healthcare Corporation
Depomed, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Neuropathic Pain Market:

In July 2022, An exclusive collaboration and commercialization agreement was signed by Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited for Novaremed's novel non-opioid investigational drug, NRD.E1, which is manufactured for the prevention and management of diabetes-related neuropathic pain and other neuropathic pain indications.

The neuropathic pain market is a rapidly growing segment of the pharmaceutical industry, driven by several key factors. One of the primary drivers of the neuropathic pain market is the rising prevalence of chronic pain. According to the National Institutes of Health (NIH), chronic pain affects approximately 50 million people in the United States, and neuropathic pain is estimated to affect between 5-10% of the population. This growing prevalence of chronic pain is driving demand for new and innovative treatments for neuropathic pain. Another factor driving growth in the neuropathic pain market is the increasing understanding of the underlying mechanisms of neuropathic pain. Research into the pathophysiology of neuropathic pain has increased the development of new drugs and treatment modalities that target specific pathways involved in the condition. In addition, the development of new and innovative therapies for neuropathic pain has also contributed to the growth of the market. For example, the introduction of new classes of drugs, such as gabapentinoids and serotonin-norepinephrine reuptake inhibitors (SNRIs), has expanded treatment options for patients with neuropathic pain. Furthermore, the increasing adoption of non-pharmacological therapies, such as neuromodulation and physical therapy, has also contributed to the expansion of the neuropathic pain market. Neuromodulation involves the use of devices, such as spinal cord stimulators and peripheral nerve stimulators, to modulate the activity of the nervous system and provide pain relief. Physical therapy can help patients with neuropathic pain to improve their physical function and manage their pain.

Despite the growth prospects, there are also several challenges faced by the neuropathic pain market. One of the significant challenges is the high cost of some of the newer drugs and treatments, which can be a barrier to access for some patients.

Neuropathic Pain Market Segmentation:

By Drug Class

Tricyclic Anti-Depressant
Anticonvulsant
Local Anaesthesia
Opioids
Steroids
Others

By Indication

Diabetic neuropathy
Chemotherapy-induced Peripheral neuropathy
Other

By Distribution Channel

Retail Pharmacies
Drug Store
Online Pharmacies

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. The United States has the greatest market share in the North American region. Regional market expansion is predicted to be fueled by the presence of major market players, sizeable pharmaceutical and biopharmaceutical industries, and higher expenditures in the country for the adoption of cutting-edge technologies throughout the course of the projection period. The industry's expansion in this region is also being fueled by several efforts taken by market participants. The market is expanding as a result of research studies that the industry's participants are performing to create effective neuropathic pain medications. The market in North America is therefore anticipated to develop throughout the course of the forecast period.

Competitive Landscape:

Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Neuropathic Pain Market By Drug Class, By Indication, By Distribution Channel and By Region.
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1. Years Considered for the Study
  3.2. Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1. Secondary Data
  1.1.1. Key Data from Secondary Sources
  1.2. Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Neuropathic Pain Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Neuropathic Pain Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Neuropathic Pain Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Neuropathic Pain Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Tricyclic Anti-Depressant
  2. Anticonvulsant
  3. Local Anaesthesia
  4. Opioids
  5. Steroids
  6. Others
8. Neuropathic Pain Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Diabetic neuropathy
  2. Chemotherapy-induced Peripheral neuropathy
  3. Other
9. Neuropathic Pain Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Retail Pharmacies
  2. Drug Store
  3. Online Pharmacies
10. North America Neuropathic Pain Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
11. Latin America Neuropathic Pain Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
12. Europe Neuropathic Pain Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
13. Asia Pacific Neuropathic Pain Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
14. Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. GCC
  2.2. Israel
  2.3. South Africa
  2.4. Rest of MEA
  3. Market Size (USD Million) Forecast for MEA 2023-2031
15. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
- 1. Pfizer, Inc.
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Johnson and Johnson Services, Inc.
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. Sanofi S.A.
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Eily Lily and Company
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. GlaxoSmithKline PLC
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Biogen Idec.
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. Bristol-Myers Squibb
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Baxter Healthcare Corporation
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. Depomed, Inc.
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
17. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients